Half-year report · Q2
6523.TEDINET S100UR3H
Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥173.9bn | 2024-04-01 → 2024-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥353.9bn | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥166.8bn | 2023-04-01 → 2023-09-30 | Cons. | Revenue IFRS |
| Operating income | ¥9.2bn | 2024-04-01 → 2024-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥4.2bn | 2023-04-01 → 2023-09-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥7.4bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | −¥13.2bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | −¥3.0bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥4.1bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥12.9bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | −¥2.5bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥4.0bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss IFRS |
| Net income | −¥2.4bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss IFRS |
| Total assets | ¥525.4bn | at 2024-09-30 | Cons. | Assets IFRS |
| Total assets | ¥564.3bn | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥570.4bn | at 2023-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥398.0bn | at 2024-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥425.2bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥127.4bn | at 2024-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥139.2bn | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥147.0bn | at 2023-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥138.8bn | at 2023-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥127.8bn | at 2024-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥139.5bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥147.4bn | at 2023-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥33.0bn | at 2024-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥47.0bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥61.4bn | at 2023-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥60.9bn | at 2023-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥13.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥41.3bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥22.7bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥5.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥21.1bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥2.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥20.9bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥39.1bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥23.6bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥32.52 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-102.48 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥-19.55 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥32.42 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥-102.48 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥-19.55 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 24.3% | at 2024-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 24.7% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 25.8% | at 2023-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | ¥1.6bn |
| Reconciling Itemsreconciling | revenue external | 2024-04-01 → 2024-09-30 | ¥1.6bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥4.3bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥48.3bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥48.3bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥6.4bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥62.6bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥62.6bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.5bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥61.5bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥61.5bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.6bn |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥172.3bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥172.3bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥13.5bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | ¥1.1bn |
| Reconciling Itemsreconciling | revenue external | 2023-04-01 → 2023-09-30 | ¥1.1bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥4.8bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥48.8bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥48.8bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥5.5bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥61.0bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥61.0bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥2.5bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥55.9bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥55.9bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥951m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥165.7bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥165.7bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥8.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 812
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | CurrentQuarterInstant_No2MajorShareholdersMember | 21870000 | |
| Shareholding ratio | CurrentQuarterInstant_No2MajorShareholdersMember | 0.1734 | |
| Number of shares held | CurrentQuarterInstant_No3MajorShareholdersMember | 12297000 | |
| Shareholding ratio | CurrentQuarterInstant_No3MajorShareholdersMember | 0.0975 | |
| Number of shares held | CurrentQuarterInstant_No4MajorShareholdersMember | 9766000 | |
| Shareholding ratio | CurrentQuarterInstant_No4MajorShareholdersMember | 0.0774 | |
| Number of shares held | CurrentQuarterInstant_No5MajorShareholdersMember | 5971000 | |
| Shareholding ratio | CurrentQuarterInstant_No5MajorShareholdersMember | 0.0473 | |
| Number of shares held | CurrentQuarterInstant_No6MajorShareholdersMember | 5714000 | |
| Shareholding ratio | CurrentQuarterInstant_No6MajorShareholdersMember | 0.0453 | |
| Number of shares held | CurrentQuarterInstant_No7MajorShareholdersMember | 799000 | |
| Shareholding ratio | CurrentQuarterInstant_No7MajorShareholdersMember | 0.0063 | |
| Number of shares held | CurrentQuarterInstant_No8MajorShareholdersMember | 738000 | |
| Shareholding ratio | CurrentQuarterInstant_No8MajorShareholdersMember | 0.0059 | |
| Number of shares held | CurrentQuarterInstant_No9MajorShareholdersMember | 507000 | |
| Shareholding ratio | CurrentQuarterInstant_No9MajorShareholdersMember | 0.0040 | |
| Number of shares held | CurrentQuarterInstant_No10MajorShareholdersMember | 424000 | |
| Shareholding ratio | CurrentQuarterInstant_No10MajorShareholdersMember | 0.0034 | |
| Number of shares held | CurrentQuarterInstant | 106083000 | |
| Shareholding ratio | CurrentQuarterInstant | 0.8410 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 211900 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 126081600 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 1260816 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 50928 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 126344428 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 1260816 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 211900 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 211900 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.0017 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant | 211900 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant | 211900 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant | 0.0017 | |
| Cash and cash equivalents IFRS | Prior1YearInstant | 47044000000 | JPY |
| Cash and cash equivalents IFRS | CurrentQuarterInstant | 32969000000 | JPY |
| Trade receivables ca IFRS | Prior1YearInstant | 73802000000 | JPY |
| Trade receivables ca IFRS | CurrentQuarterInstant | 63711000000 | JPY |
| Inventories ca IFRS | Prior1YearInstant | 52651000000 | JPY |
| Inventories ca IFRS | CurrentQuarterInstant | 54737000000 | JPY |
| Other financial assets ca IFRS | Prior1YearInstant | 4775000000 | JPY |
| Other financial assets ca IFRS | CurrentQuarterInstant | 4152000000 | JPY |
| Other current assets ca IFRS | Prior1YearInstant | 9575000000 | JPY |
| Other current assets ca IFRS | CurrentQuarterInstant | 9987000000 | JPY |
| Current assets IFRS | Prior1YearInstant | 187849000000 | JPY |
| Current assets IFRS | CurrentQuarterInstant | 165557000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |